Black Diamond Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $9.0 million.
“Net loss for the first quarter of 2026 was $9.0 million, as compared to net income of $56.5 million for the same period in 2025.”
Black Diamond Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Black Diamond Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Erika Jones was appointed as principal financial officer at Black Diamond Therapeutics, Inc..
“Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.”
Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer at Black Diamond Therapeutics, Inc..
“On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024”
Black Diamond Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $18.2 million.
“Net loss for the first quarter of 2024 was $18.2 million”
Prakash Raman was appointed as Director at Black Diamond Therapeutics, Inc..
“the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director”
Wendy L. Dixon resigned as Director at Black Diamond Therapeutics, Inc..
“Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board”
Alexander Mayweg resigned as Director at Black Diamond Therapeutics, Inc..
“Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).”
Black Diamond Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $82.4 million.
“Net loss for the year ended December 31, 2023 was $82.4 million compared to $91.2 million for the year ended December 31, 2022.”
Black Diamond Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $19.4 million.
“Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.